2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2033

Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection
Abstract Number: 1639

Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Abstract Number: 467

Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
Abstract Number: 1667

Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Abstract Number: 264

Clinical Phenotype and Response to Treatment in Adult-Onset Still’s Disease with MEFV Variants
Abstract Number: 3197

Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Abstract Number: 2487

Clinical Practices Participating in a Quality Improvement Project Make Progress in Implementing Population Management
Abstract Number: 540

Clinical Relevance of Etanercept Levels and Anti-Etanercept Antibodies in Long-Term Treatment of Rheumatoid Arthritis Patients
Abstract Number: 653

Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2860

Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2687

Clinical Significance of Patient-Reported Pain and Stiffness at Each Joint Level in the Evaluation of Patients with Rheumatoid Arthritis
Abstract Number: 627

Clinical Subsets and Presenting Features in Primary Sjögren’s Syndrome: Results from a Single Center Inception Cohort Study
Abstract Number: 2619

Clinical Usefulness of Periodic Detection of Serum 14-3-3Î· for Predicting Efficacy of Tocilizumab in RA
Abstract Number: 2758

Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Abstract Number: 1317

Clinical Utility of Joint Space Width and X-Ray Radiogrammetry in RA: Markers for Early Radiographic Progression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].